Clinical Trial Update: The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease [Phase 4]

View source ↗

Summary

Phase 4 pediatric trial evaluating the effect of Velaglucerase alfa on skeletal development in Gaucher disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type
• Gaucher Disease Type 3

Drugs mentioned

• VPRIV (VELAGLUCERASE ALFA)

Snippet

Sponsor: Baylor Research Institute | Conditions: Gaucher Disease Type 1, Gaucher Disease Type 3 | Phase 4 | Status: WITHDRAWN